Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 5;14(8):1639.
doi: 10.3390/pharmaceutics14081639.

Analysis of Biologics Molecular Descriptors towards Predictive Modelling for Protein Drug Development Using Time-Gated Raman Spectroscopy

Affiliations

Analysis of Biologics Molecular Descriptors towards Predictive Modelling for Protein Drug Development Using Time-Gated Raman Spectroscopy

Jaakko Itkonen et al. Pharmaceutics. .

Abstract

Pharmaceutical proteins, compared to small molecular weight drugs, are relatively fragile molecules, thus necessitating monitoring protein unfolding and aggregation during production and post-marketing. Currently, many analytical techniques take offline measurements, which cannot directly assess protein folding during production and unfolding during processing and storage. In addition, several orthogonal techniques are needed during production and market surveillance. In this study, we introduce the use of time-gated Raman spectroscopy to identify molecular descriptors of protein unfolding. Raman spectroscopy can measure the unfolding of proteins in-line and in real-time without labels. Using K-means clustering and PCA analysis, we could correlate local unfolding events with traditional analytical methods. This is the first step toward predictive modeling of unfolding events of proteins during production and storage.

Keywords: CD; DLS; K-means clustering; PCA; Raman spectroscopy; biologics; in-line measurement; pharmaceutical proteins; protein unfolding; tryptophan fluorescence.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 2
Figure 2
Averaged and normalized Time-gated spectra of IgG (glycosylated; blue; N = 11) and IgG (non-glycosylated; red; N = 6) at (A) 25 °C, (B) and at 65 °C. Individual, non-processed, and non-normalized Time-gated spectra (i.e., raw data) are shown in Figures S11 and S12. Regions of significance in respect of the glycosylation status of proteins, as determined by Brewser et al. (2011) [46] are shown in green. Raman values of significance, as presented in Table S5, are depicted in bold and red.
Figure 1
Figure 1
Averaged (N = 11) and normalized time-gated spectra of pepsin at 25 °C (blue) and 65 °C (red). (A,B) correspond to the individual, non-processed, and non-normalized Time-gated spectra as presented in the left and right panes in Figure S10. (i.e., raw data). Raman values of significance, as presented in Table S4 (supplementary data), are depicted in bold and red.
Figure 3
Figure 3
Averaged (N = 11) and normalized Time-gated spectra of (A) ovalbumin at 25 °C (blue) and 50 °C (red), and (B) LmTIME65Q at 25 °C (blue) and 86 °C (red) correspond to the individual, non-processed, and non-normalized time-gated spectra as presented in Figures S19 and S20 (i.e., raw data). Raman values of significance, as presented in Tables S6 and S7, are depicted in bold and red.

Similar articles

Cited by

References

    1. Casteleijn M.G., Richardson D. Engineering Cells and Proteins—Creating pharmaceuticals. Eur. Pharm. Rev. 2014;2014:4.
    1. Leader B., Baca Q.J., Golan D.E. Protein therapeutics: A summary and pharmacological classification. Nat. Rev. Drug Discov. 2008;7:21–39. doi: 10.1038/nrd2399. - DOI - PubMed
    1. Sauna Z.E., Lagassé H.A.D., Alexaki A., Simhadri V.L., Katagiri N.H., Jankowski W., Kimchi-Sarfaty C. Recent advances in (therapeutic protein) drug development. F1000Research. 2017;6:113. doi: 10.12688/f1000research.9970.1. - DOI - PMC - PubMed
    1. Quianzon C.C., Cheikh I. History of insulin. J. Community Hosp. Intern. Med. Perspect. 2012;2:18701. doi: 10.3402/jchimp.v2i2.18701. - DOI - PMC - PubMed
    1. Zheng K., Bantog C., Bayer R. The impact of glycosylation on monoclonal antibody conformation and stability. mAbs. 2011;3:568. doi: 10.4161/mabs.3.6.17922. - DOI - PMC - PubMed

LinkOut - more resources